Eight cosmid clones were regionally assigned to small subregions of chromosome 22 by hybridization with a total of 22 somatic cell hybrids. One cosmid was localized to the proximal part of 22q which contained the region commonly deleted in the DiGeorge syndrome. Seven cosmids showing restriction fragment length polymorphisms were localized to the telomeric region distal to the MB locus, which was reported to be frequently deleted in sporadic meningioma. These cosmids, when finely mapped and ordered, are considered useful for the identification of genetic alterations on this chromosome arm.
INTRODUCTION
Chromosome 22, one of the shortest chromosomes among human genomes, is thought to contain several genes responsible for tumorigenic disorders or congenital malformation syndromes. Loss of heterozygosity (LOH) on 22q has been reported in meningiomas, colorectal cancers, pheochromocytomas, and breast cancers, indicating the possible existence of tumor suppressor(s) on the chromosome arm (Dumanski et al., 1987; Okamoto et al., 1988; Tanaka et al., 1992; Shin et aI., 1993; Chert et al., 1991) . Moreover, in the case of the DiGeorge syndrome (DGS), deletion of a certain region of 22qll is thought to be closely related with this disease (Driscoll et aI., 1992) . A previous report of ours described how a total of 108 cosmid markers on human chromosome 22 were newly isolated and roughly mapped with five somatic cell hybrids into four different regions of chromosome 22 (Kurahashi et al., 1994) . Of these, 64 detected restriction fragment length polymorphism (RFLP) systems that should be very useful for linkage mapping of the chromosome and for detection of LOH in several human tumors. In this study, eight of the 108 cosmid clones, including seven RFLP markers, were selected for the usefulness of their location and were localized to small subregions by mapping on a panel of 22 rodent/human somatic cell hybrids containing a veriety of partial segment of human chromosome 22.
MATERIALS AND METHODS
Of 108 cosmids on chromosome 22, eight cosmids, seven of which had been roughly mapped on 22q12.1-qter and one to 22pter-qll.2, were selected (Kurahashi et al., 1994) . A total of 22 rodent/human somatic cell hybrids were used for the mapping procedure, most of which had been developed by fusion of human cell lines, each carrying a different chromosome 22 translocation, with a Chinese hamster ovary cell line deficient in adenylosuccinate lyase activity (Delattre et al., 1991) . References for the origin of the other hybrids are as follows: X/22-33-11TG, 1/22AM27 (Geurts van Kessel et al., 1980) ; CERCH-h, -s (Hors-Cayla et aI., 1981); WESP2A (de Klein eta/., 1982) ; KAG, DAG (Boyd et al., 1988) ; NF13 (Ledbetter et al., 1989) .
Southern hybridization was performed with these cosmids as probes to a panel of the 22 hybrids. High molecular weight DNAs were completely digested with HindIII, separated on agarose gel, and then blotted onto nylon membranes. Cosmid DNA was radiolabeled with [~-32p] dCTP by means of the random-primer method. The radiolabeled cosmids and the membranes were then prehybridized with 200 ag/ml of sonicated human placental DNA in a hybridization solution at 65~ for 24 h to reduce the background effects of human repetitive sequences. Hybridization was performed overnight at 65~ in a solution containing 10 ~ SDS, 7 ~ polyethylene glycol 8000, and 200 ~xg/ml of human placental DNA. After hybridization, the blots were washed twice at room temperature with 2x SSC, then twice at 65~ with 0.1 x SSC and 0.1~ SDS for 15 min each, and exposed to Kodak XAR films at -80~ for 1-3 days.
RESULTS
The panel of rodent/human somatic cell hybrids allowed us to assign eight cosmids to small subregions of chromosome 22. Regional localization of the cosmids is schematically shown in Fig. 1 . Interestingly, cHKAD-26 contained Mapping of eight cosmids as deduced from the characterization of the panel of somatic cell hybrids. Rectangles indicate the portion of the chromosome 22 present in the hybrids. For a posiitve Southern blot signal, "1" is entered, and for a negative one, "0." The name of the hybrids are indicated at the top, while the nero of the cosmid clones are listed on the right. The data for D22S24, D22S9, IGLV, BCR, MB, and D22S23 were derived from the previous study (Delattre et ak, 1991) . The order in which cHKAD-41, ct-IKA-66, and cI-IKA-89 are listed is arbitrary. On the left are indicated the groups that are explained in the reference, and the subgroups that were deduced in this study. A. Mapping of cHKAD-26 near the centromeric region of 22q. 9. Mapping of seven polymorphic clones to the telomeric region of 22q.
multicopy sequences specific to this small subregion. Some of the cosmids detected new subregions which had not been defined in the previous report (Delattre et al., 1991) : Group 11 could be divided into two and Group 12 into three subregions in this study.
In addition, cHKAD-26, cHKAll0, and cHKA212 cross-hybridized to mouse and/or Chinese hamster DNAs, indicating that these cosmids contain evolutionarily conserved sequences (data not shown). Vol. 39, No 2, 1994 DISCUSSION Region-specific DNA fragments have been powerful tools for the investigation of genetic alterations underlying a large number of human diseases. Although a large set of polymorphic or non-polymorphic markers on chromosome 22 has been developed in recent years, additional markers are required for construction of more detailed linkage map of the chromosome. The eight cosmid markers that were finely mapped to small subregions of chromosome 22 should be a valuable source for genetic analysis of the chromosome. In the panel of hybrids used for this study, some of the cosmids detected new subregions which had not been defined in the previous report (Delattre et al., 1991) . This panel thus proved to be very useful for mapping procedures to divide chromosome 22 into more refined subregions. Detailed mapping of the remaining cosmids with the aid of the same panel of hybrids is in progress.
DGS is a developmental field defect that involves the third and fourth pharyngeal pouches, causing absence of thymus and parathyroid glands, cardiac conotruncal abnormalities, and facial dysmorphism. A high-resolution banding technique has recently revealed that deletion of 22qll.21-qll.23 is closely related with the syndrome (Wilson et al., 1992) . Dosage analysis of cHKAD-26, which had been mapped near the centromeric region of 22q, proved it to be located in the submicroscopically deleted region of two DGS patients (Kurahashi et al., 1994) . The present study localized cHKAD-26 within the region between D22S9 and IGLV, where the region commonly deleted in DGS and identified in a previous report lies (Fibson et al., 1990) . Therefore, it was physically confirmed that cHKAD-26 locates in the region commonly deleted in DGS. Interestingly, this cosmid contains unique sequences cross-hybridizing to rodent DNAs and multi-copy sequences specific to this small subregion of chromosome 22 (data not shown). A detailed analysis of the locus, including cosmid walking and cDNA isolation, is now in progress.
LOH on 22q is frequently observed in meningioma, pheochromocytoma, colorectal cancei, and breat cancer. Although the neurofibromatosis 2 (NF2) gene has recently been isolated (Trofatter et al., 1993; Rouleau et al., 1993) , there still remains the possibility that additional tumor suppressors associated with development of these tumors exist on the chromosome. Seven clones that were able to detect RFLPs were finely mapped and ordered in the telomeric region of 22q distal to the MB locus, which was reported to be frequently deleted in sporadic meningioma. A recent investigation of ours showed that several cases of sporadic meningioma had lost the distal part of 22q, while LOH was more frequently observed in the telomeric region of 22q in colorectal cancer (unpublished data), indicating that other tumor suppressor gene(s) than the NF2 gene may exist in this chromosomal region. The cosmids used in this study should aid the construction of a deletion map to localize the tumor suppressor gene(s) responsible for colorectal cancer and/ or sporadic meningioma.
